Old Web
English
Sign In
Acemap
>
Paper
>
579 Rationale and design for the Kallikrein Inhibitor in Netherton Syndrome (KINS) pivotal clinical trial
579 Rationale and design for the Kallikrein Inhibitor in Netherton Syndrome (KINS) pivotal clinical trial
2020
K.W. Johnson
Alain Hovnanian
Joyce M.C. Teng
Amy S. Paller
Keith A. Choate
Peter M. Elias
Z Laura
T. Nguyen
D. Smith
A. Hsu
L. Alani
C Lai
L. Hsu
Keywords:
Clinical trial
Netherton syndrome
kallikrein inhibitor
Immunology
Biology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]